Pharvaris N.V. presented data at the Consortium of Independent Immunology Clinics (CIIC) Spring 2026 Conference in Arlington, Texas, demonstrating that its 40 mg extended‑release (XR) tablet and 20 mg immediate‑release (IR) capsules of deucrictibant can be co‑administered safely.
The presentation addressed a key clinical question for patients who require on‑demand relief while on prophylaxis, showing that human exposure modeling and non‑clinical data support adequate safety margins for the combined use of the two formulations.
Chief Medical Officer Peng Lu, M.D., Ph.D., said, "These safety data, combined with the post‑hoc efficacy analyses of mechanism‑on‑mechanism treatment of breakthrough attacks, provide evidence for the potential of the combined use of deucrictibant as a prophylactic treatment and as an on‑demand medication. Bradykinin‑mediated angioedema can be prevented by administering a bradykinin B2 receptor antagonist that exceeds the therapeutic threshold to compete with bradykinin. If the plasma concentration of drug drops below this threshold, a person may be susceptible to a breakthrough attack; rapid exposure to an on‑demand treatment using the same mechanism could be a compelling treatment approach in this scenario. We look forward to further exploring this strategy."
The safety data support Pharvaris’s strategy of offering a single oral molecule for both prophylaxis and acute treatment of hereditary angioedema (HAE). The company is advancing pivotal Phase 3 studies—CHAPTER‑3 for prophylaxis and RAPIDe‑3 for on‑demand therapy—with topline data expected in Q3 2026 for CHAPTER‑3 and marketing‑authorization applications for the IR capsule in preparation.
In the competitive HAE landscape, new therapies such as garadacimab, donidalorsen, and sebetralstat provide alternative mechanisms and administration routes. Pharvaris’s dual‑formulation approach could differentiate its product by combining the convenience of oral therapy with the efficacy of a bradykinin B2 receptor antagonist for both indications.
revised_sentiment_rating":3}]}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.